BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld MedTech
Home
» FDA establishes new interoperable insulin pump device class – with Tandem up first
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA establishes new interoperable insulin pump device class – with Tandem up first
Feb. 19, 2019
By
Stacy Lawrence
No Comments
Tandem Diabetes Care Inc. saw its shares climb almost 20 percent this week, just as it became the first company to have a product classified in a new FDA category: Alternate Controller Enabled Infusion Pumps (ACE pumps).
BioWorld MedTech